TickerFacts.

Exelixis, Inc. (EXEL): Share Repurchases

Annual figures by period end, from SEC filings.

$947.51M
Year ended 2026-01-02, Fiscal 2025
$1.11B
Trailing 12 months to 2026-07-03
2021-12-31: $02022-12-30: $02023-12-29: $550.38M2025-01-03: $652.03M2026-01-02: $947.51M$947.51M
2021-12-31 Share Repurchases (USD) 2026-01-02
Period endedShare RepurchasesChange YoYSource filing
2026-01-02, Fiscal 2025$947.51M+45.3%2026-02-10, From 2025-01-04
2025-01-03, Fiscal 2024$652.03M+18.5%2026-02-10, From 2023-12-30
2023-12-29$550.38Mn/a2026-02-10, From 2022-12-31
2022-12-30$0n/a2025-02-11, From 2022-01-01
2021-12-31$0n/a2024-02-06, From 2021-01-02

Share Repurchases at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShare RepurchasesChange YoY
Exelixis, Inc. (EXEL)2026-01-02$947.51M+45.3%
Qiagen N.V. (QGEN)2025-12-31$280.09M-4.1%
Moderna, Inc. (MRNA)2025-12-31$2.00Mn/a
Neurocrine Biosciences Inc (NBIX)2025-12-31$167.70M-44.1%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$342.37M+36.9%
Bio-Techne Corp (TECH)2026-06-30$41.67M-84.9%
Repligen Corp (RGEN)2025-12-31$0n/a
Biogen Inc. (BIIB)2024-12-31$0n/a
ADMA Biologics, Inc. (ADMA)2025-12-31$31.94Mn/a

Compare EXEL, QGEN, MRNA, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗